Mar. 25 at 11:32 AM
$SMTI
Sanara MedTech reported strong Q4 2024 financial results with net revenue increasing 49% year-over-year to
$26.3 million.
Full-year 2024 revenue grew 33% to
$86.7 million.
Q4 highlights include:
Gross profit rose 51% to
$24.1 million with 91% margin
Operating loss of
$0.4 million compared to
$0.2 million loss in Q4 2023
Net loss of
$1.7 million versus
$0.3 million loss in Q4 2023
Adjusted EBITDA of
$0.9 million, up from
$0.4 million
The growth was primarily driven by increased sales of soft tissue repair products, particularly CellerateRX Surgical and BIASURGE.
The company plans to invest
$7.5-10.0 million in Tissue Health Plus segment in H1 2025, with a pilot program launch expected in Q2.
As of December 31, 2024, Sanara had
$15.9 million cash and
$30.5 million in debt obligations.
